NEW YORK (GenomeWeb News) – Detroit R&D has landed an $800,000 grant to continue developing its technology for screening a biomarker for prostate cancer, the company said today.
 
Under the two-year Phase II Small Business Innovation Research award, Detroit R&D will pursue research into ELISA and microarray kits to screen non-steroidal inflammatory drug-activated gene, or NAG-1, also known as macrophage inhibitory cytokine-1 or prostate-derived factor-15.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.